Core Research

Melanocortin Comparison Matrix

Melanotan I (MT-I), Melanotan II (MT-II) and PT-141/bremelanotide are distinct melanocortin research entities. They share relationships to α-melanocyte-stimulating-hormone signalling but differ in scaffold and in how receptor and cell studies should be interpreted. A research comparison should distinguish molecular identity, receptor subtype, cell model and measured endpoint rather than rank them for human pigmentation, sexual function or other personal outcomes.

Research Use Only: Core Research supplies these materials for controlled laboratory research only. This matrix is not a treatment comparison and provides no human or veterinary administration guidance.

Structural and evidence comparison

Research feature MT-I / [Nle⁴,D-Phe⁷]-α-MSH MT-II PT-141 / bremelanotide
General structural class Modified, linear α-MSH-related analogue Cyclised heptapeptide melanocortin analogue Closely related cyclised heptapeptide, separate terminal chemistry
Core research context Melanocortin receptor and pigment-cell assays Multi-subtype melanocortin pharmacology Melanocortin receptor pharmacology and its own distinct structure
Important distinction Do not infer universal MC1R selectivity from a pigment-cell result Potency changes with receptor subtype and assay Not merely another name or formulation for MT-II
Analytical requirement Exact linear sequence and terminal form Exact cyclic structure and terminal form Exact cyclic structure and terminal form; distinct from MT-II
Core Research record MT-I 10mg MT-II 10mg PT-141 10mg

This is a structural and study-design matrix, not a head-to-head potency test. It does not establish equal concentrations, effects or lot quality across the three products.

What makes melanocortin receptor subtype data difficult to compare?

Melanocortin-receptor family members (including MC1R, MC3R, MC4R and MC5R) can respond differently to the same ligand. Activity estimates depend on the species, engineered receptor-expression system, competing tracer or functional readout and assay conditions. Binding affinity, receptor activation and tissue-level response are not synonymous.

A receptor-panel paper may report activity at several subtypes under one method. If another paper uses a different cell line and endpoint, the numbers are not necessarily a valid like-for-like ranking. A selective result for a designed derivative of MT-II does not automatically characterise the unsubstituted parent MT-II material.

What does the MT-I analogue literature show?

MT-I research often uses the [Nle⁴,D-Phe⁷]-α-MSH sequence, a modified linear α-MSH-related analogue. In Jiang and colleagues’ human melanoma-cell-line study, 17 lines were investigated under the conditions described. Only one line consistently showed enhanced tyrosinase activity in the initial experiment, while effects on growth-related measurements and morphology varied by context.

The important point is heterogeneity. A cell-line pigment-enzyme result is not universal MC1R selectivity, and it does not establish clinical pigmentation behaviour or a cosmetic use for a laboratory research product.

What does MT-II add to receptor pharmacology?

MT-II is a cyclised α-MSH-related analogue that has been used as a relatively broad melanocortin receptor probe. Original receptor and analogue work shows why cyclisation and stereochemistry matter: small structural changes can alter subtype potency or even the direction of activity in a receptor system. A melanocortin ligand review summarises primary panel results and their assay contexts; it is secondary synthesis, not a measurement of Core Research MT-II material.

A study of a purposely modified MT-II analogue in a frog chromatophore system (Gao and colleagues, 2015) does not establish the same properties for the parent MT-II or for a human receptor panel. It is included to explain why analogue identity and species cannot be omitted from a citation.

Why is PT-141 a separate molecular identity?

PT-141/bremelanotide is structurally related to MT-II but must be named and documented separately. One useful distinction is the C-terminal form reported by reference chemical descriptions: MT-II is commonly specified with a C-terminal amide, while bremelanotide’s reference structure has a free carboxylic-acid terminus. PubChem’s MT-II record and bremelanotide record provide chemical-entity references; the exact material in a supplier lot must still come from that lot’s evidence.

An independently regulated bremelanotide pharmaceutical formulation exists in some jurisdictions, but its authorisation, testing, manufacturing controls or finished-device properties do not transfer to a Core Research RUO vial. The laboratory comparison concerns the underlying chemical species and the limits of receptor studies, not product substitution.

Interpreting apparently conflicting receptor results

A good record notes whether the paper measured binding displacement, cAMP signalling, pigment-enzyme activity, gene expression or an organism-level endpoint. A ligand may bind a receptor without producing the same downstream signal observed with another assay design. Receptor expression and species can also affect the observed pattern.

A paper reports… It can support… It cannot automatically support…
Binding affinity in transfected cells Relative binding under that receptor assay Whole-organism clinical efficacy
cAMP or another functional receptor readout Signalling under the defined exposure and system Equal selectivity in another species
Tyrosinase change in melanoma cells A model-specific cellular response Every cell line responding identically
A pharmacology result for a modified analogue That exact tested analogue’s properties The parent molecule’s properties

How to use the Core Research catalogue and references

Choose the precise entity and research endpoint first. Then match source identity, species, receptor and assay to the laboratory’s question. For lot acceptance, use Batch Documentation and the CoA-reading guide. Neither a paper nor a chemical database automatically authenticates a stocked vial, refill or pen.

The dedicated MT-II versus PT-141 comparison explains the terminal-form distinction in more depth, while MT-I versus MT-II owns the specific linear-versus-cyclic question. These are adjacent guides, not duplicate efficacy rankings.

Selected references

  1. Jiang J et al. The melanotropic peptide [Nle4,D-Phe7] alpha-MSH stimulates human melanoma tyrosinase activity and inhibits cell proliferation. Pigment Cell Research, 1995. PMID: 8789740.
  2. Gao L et al. Analogue of Melanotan II (MTII): A Novel Melanotropin with Superpotent Action on Frog Skin. Protein & Peptide Letters, 2015. PMID: 26095376. A modified analogue, not an assay of a commercial MT-II vial.
  3. Bench-Top to Clinical Therapies: A Review of Melanocortin Ligands from 1954 to 2016. 2017. PubMed Central. Secondary review of receptor assay findings.
  4. U.S. National Library of Medicine PubChem. MT-II chemical entity and bremelanotide chemical entity. Structural references only; no supplier-batch conclusions.